194) in patients with systemic sclerosis (SSc) compared to healthy controls by measuring |
195) te normal mimicry in children with ASD as compared to healthy controls, but that in |
196) intervals, starting at the diagnosis, and compared to healthy controls. |
197) ference has been evidenced in AS patients compared to healthy controls. |
198) sture, in patients with Meniere's disease compared to healthy general population. |
199) O, P < 0.0001) in AWD/CDH infants compared to healthy infants at birth but h |
200) atic body areas differ in EDS-HT patients compared to healthy subjects. |
201) hreshold in a group of rheumatic patients compared to healthy subjects. |
202) antly reduced inspiratory muscle strength compared to healthy term born infants but |
203) Compared to their counterparts who did not |
204) The predicted models were compared to their CT joint models. |
205) tions in African Americans with NSCLC, as compared to their White counterparts. |
206) 6 h produced maximum inhibition of CFU compared to their controls for both microo |
207) owed a statistically significant decrease compared to their controls in colony formi |
208) tly more common for gender-referred girls compared to their female siblings on eithe |
209) ese children may be at heightened risk as compared to their nonexposed peers for the |
210) six randomly selected NP with spores were compared to their respective control NP. |
211) 0.01) to be exposed to solid fuel smoke compared to their rural counterparts. |
212) Compared to conventional motion compensati |
213) ssures and small white matter tracks when compared to conventional MRI and DTI. |
214) The performance was compared to conventional motion compensate |
215) 2.69-fold increased in bioavailability as compared to conventional tablet formulatio |
216) roved dose conformity to the tumor target compared to conventional three-dimensional |
217) y increases adhesion to eroded dentin, as compared to conventional treatment. |
218) Compared to controls, ACE2 and Mas recepto |
219) Compared to controls, electrostimulated ce |
220) In addition, compared to controls, CI users displayed a |
221) weeks after injection of 10% OC-Fe3O4 NPs compared to controls, but the effect was t |
222) < 0.016) in patients at diagnosis compared to controls, in accordance with r |
223) y of laser groups was significantly lower compared to placebo and control groups (p |
224) The end of pain occurred earlier in laser compared to placebo and control groups (p |
225) until exhaustion increased significantly compared to placebo by 4.12 s (95% CI 1.21 |
226) occlusal splint therapy (p < 0.05) compared to placebo group (p < 0.05 |
|